CD8A and melanoma: The Lipo-MERIT trial demonstrated strong CD4+ and CD8+ T cell induction along with durable objective clinical benefit in unresectable melanoma patients treated with a poly-antigenic liposomal RNA vaccine with or without combination with anti-PD1 checkpoint blockade therapy [32].